As a journalist, I often wonder about the exact location of the fine line that separates justified enthusiasm from self-serving hype, especially when it comes to clinical trials. Last week, I asked the question of [more]
With increasing numbers of cancer drugs being approved on shorter trials that involve fewer patients, getting accurate reports of adverse events and side effects after approval is increasingly important. Maria Delaney reports on efforts to [more]
A new model for caring for depression in cancer patients shows how much can be achieved even on a tight budget. That being diagnosed with cancer carries an increased risk of depression is perhaps not [more]
Cytotoxic agents are conventionally dosed on the basis of the maximum tolerated dose defined in phase I trials. A study assessing adverse events in over 2,000 patients treated with molecularly targeted agents suggests a need [more]
Good clinical trials are proposed by clinicians, have the potential for real patient benefit and increase knowledge about the disease, says Pinuccia Valagussa, who is dedicated to helping more centres join trials. Download full article
Pelvic lymphadenectomy offers no therapeutic benefit to women diagnosed with early-stage endometrial cancer according to a new study. Lymphadenectomy can only be recommended as part of a clinical trial in this disease setting; however, it [more]